These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31810594)

  • 21. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond methamphetamine: Documenting the implementation of the Matrix model of substance use treatment for opioid users in a South African setting.
    Magidson JF; Gouse H; Burnhams W; Wu CY; Myers B; Joska JA; Carrico AW
    Addict Behav; 2017 Mar; 66():132-137. PubMed ID: 27940387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.
    Fox AD; Chamberlain A; Frost T; Cunningham CO
    Subst Abus; 2015; 36(2):155-60. PubMed ID: 25837290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Buprenorphine on Methamphetamine Cravings.
    Salehi M; Emadossadat A; Kheirabadi GR; Maracy MR; Sharbafchi MR
    J Clin Psychopharmacol; 2015 Dec; 35(6):724-7. PubMed ID: 26468683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF; Black RA; Severtson SG; Dart RC; Green JL
    J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.
    Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI
    Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-buprenorphine opioid utilization among patients using buprenorphine.
    Daubresse M; Saloner B; Pollack HA; Alexander GC
    Addiction; 2017 Jun; 112(6):1045-1053. PubMed ID: 28107580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
    Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
    J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.